Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

• WAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025

• Phase 3 RECONNECT Study in Fragile X Syndrome (FXS) Designed to Confirm Positive Findings from the Phase 2/3 CONNECT Study; Opportunity to Address Unmet Needs of 80,000 Patients with FXS

• On Track to Begin First-in-Human Clinical Trial with BP1.15205, a Potential Best-In-Class Orexin-2 Agonist, in 2H 2025

• Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028

Conference Call and Webcast to be Held Today at 8:30 a.m. ET

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced plans to announce topline data from its phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome in Q3 2025. The company also announced 16% year-over-year revenue growth for WAKIX® in Q2 2025, driven by strong patient adds of 400 for the quarter, continuing its trajectory toward blockbuster status in narcolepsy and a potential $1B+ market opportunity. The company continues to build on four consecutive years of revenue growth and profitability. With over $672 million in cash and investments, Harmony has further strengthened its financial position, solidifying its unique profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term growth potential.

“The approximately 80,000 U.S. families in the Fragile X community have been waiting far too long for a treatment that addresses the core symptoms of this serious condition. We are on track to announce the Phase 3 readout for ZYN002 in the third quarter, which represents a potentially transformative moment for these patients and for Harmony. With global rights to this product, if successful, we see a meaningful opportunity to address this significant unmet medical need both in the U.S. and around the world,” said Jeffrey M. Dayno, M.D., President and CEO of Harmony Biosciences. “Based on the strength of our commercial business, our continued profitability and commitment to patients, Harmony is building a commercially durable business with a robust pipeline and clear path to delivering long-term value for patients, providers, and shareholders alike.”

Franchise Highlights

Neurobehavioral Franchise

ZYN002

• Topline Data from the Phase 3 registrational trial of ZYN002 in Fragile X syndrome on track for Q3 2025.
  • RECONNECT study is designed to confirm the statistically significant and clinically meaningful findings from the prespecified analysis of the primary outcome in the subgroup of patients with complete methylation from the Phase 2/3 CONNECT study.
    • Over 50% of patients in the CONNECT study demonstrated clinically meaningful improvements in social avoidance and irritability/disruptive behaviors.
  • ZYN002 is an innovative product: 100% purely synthetic, pharmaceutically manufactured cannabidiol devoid of THC, in a patent-protected, permeation-enhanced gel formulation.
  • Unique mode of transdermal delivery (through the skin) that results in stable blood levels to maximize efficacy.
    • This mode of delivery is also patient friendly for those with FXS, who often have difficulty swallowing tablets, enhancing compliance.
  • Over 8 years of long-term safety, tolerability and durability of effectiveness data in patients with FXS.
    • The most common TEAE was mild to moderate application site skin reactions, in less than 7% of patients, which was transient and self-resolving.
• Potential to be the first and only approved treatment for patients with FXS; 80,000 patients in the U.S. and Harmony possesses global rights.
• Prepared to initiate Phase 3 registrational trial in 22q11.2 deletion syndrome (22q), another neurobehavioral disorder with similar symptoms to FXS, in Q4 2025.

Sleep/Wake Franchise

WAKIX in Narcolepsy

• Net Revenue was $200.5 million for Q2 2025.
• 2025 Net Revenue on track to achieve $820 to $860 million.
• Increase of 400 average patients to achieve 7,600 average patients in Q2 2025.

Pitolisant HD (high dose)

• Phase 3 registrational trials in both narcolepsy and IH to initiate in Q4 2025 with target PDUFA dates in 2028.
• Higher dose and optimized pharmacokinetic profile designed for greater efficacy without compromising safety and tolerability profile.
• Phase 3 registrational trial in narcolepsy designed for greater efficacy in excessive daytime sleepiness and cataplexy; includes endpoint on narcolepsy-related fatigue in pursuit of a differentiated label.
• Phase 3 registrational trial in IH to include endpoint on sleep inertia in pursuit of a differentiated label.
• Utility patents filed for pitolisant HD with potential exclusivity to 2044.

Pitolisant GR (gastro-resistant)

• Topline data readout from pivotal BE study anticipated in Q4 2025 with potential PDUFA date in 2026.
• Designed to address potential for treatment-related GI side effects as patients with narcolepsy commonly experience GI symptoms related to their underlying disease (up to 90%).
• Provides an ability for patients to start at therapeutic dose range without the need for titration.
• Utility patents filed for pitolisant GR with potential exclusivity to 2044.

Orexin-2 receptor agonist (BP1.15205)

• First-in-human study to commence in 2H 2025 with clinical data anticipated in 2026.
• Comprehensive and compelling preclinical safety and efficacy data presented at SLEEP 2025.
• Potential to be best-in-class orexin-2 receptor agonist based on a novel chemical scaffold, preclinical potency, selectivity, safety and efficacy data, as well as its potential for once-a-day dosing.

Rare Epilepsy Franchise

EPX-100 (clemizole hydrochloride)

• One of the most advanced development programs in the 5HT2 (serotonin) agonist class.
• Enrollment ongoing for Phase 3 registrational trial in Dravet syndrome (ARGUS Study) with topline data anticipated in 2026.
• Enrollment ongoing for Phase 3 registrational trial in patients with Lennox-Gastaut syndrome (LIGHTHOUSE Study) with topline data anticipated in 2026.

EPX-200 (lorcaserin hydrochloride)

• Proven mechanism of action in developmental and epileptic encephalopathies (DEEs) confirmed via non-clinical and clinical data.
• Currently in IND-enabling stage.

Business Development

• Harmony Biosciences entered into a research collaboration with CiRC Biosciences, a regenerative medicine company developing novel therapies based on cellular reprogramming, focused on developing novel regenerative cellular therapies to replace and restore function in patients with serious, refractory neurological disorders.
• This collaboration is strategically aligned with Harmony’s pipeline and focused on treatments for refractory epilepsy and treatment-resistant narcolepsy. It could potentially result in the next generation of innovative, disease-modifying therapies for these neurological diseases using allogeneic, off-the-shelf, readily sourced cGMP-grade cell lines without the use of stem cells, enabling a significant competitive and manufacturing advantage.
• Harmony Biosciences paid $15 million upfront to CiRC in conjunction with this research collaboration agreement. We have an option to acquire an exclusive license for each program (refractory epilepsy and treatment-resistant narcolepsy) after the establishment of preclinical in vivo proof of concept, for an aggregate of $10 million in milestone and option fee payments for each program. The agreement includes customary milestones and royalties that we may be obligated to pay in the future based on the continued development and potential commercialization of each of these therapies.

Strong Patent Position for WAKIX with Third Settlement in ANDA Litigation

• On June 5th, Harmony announced a settlement agreement with Lupin Limited, one of the largest generic manufacturers, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride).
• As part of the agreement, litigation in the United States District Court for the District of Delaware was dismissed, and Lupin received a license to launch its generic product no earlier than January 2030 (or July 2030 with pediatric exclusivity), or earlier under certain circumstances.
• Harmony remains committed to vigorously defending its intellectual property and continues to litigate its consolidated patent infringement case against several other companies that have filed ANDAs seeking approval for generic versions of WAKIX® (pitolisant hydrochloride).

Second Quarter 2025 Financial Results

Harmony Biosciences reported net product revenue of $200.5 million for the quarter ended June 30, 2025, compared to $172.8 million for the same period in 2024, representing 16% year-over-year growth. This performance was primarily driven by strong commercial sales of WAKIX, reflecting both continued organic demand within the large narcolepsy market opportunity (approximately 80,000 diagnosed patients in the U.S.) and the product's broad clinical utility. Our commercial efforts reached approximately 9,000 healthcare providers during the quarter, including about 5,000 who do not participate in an oxybate REMS program, demonstrating successful penetration across both traditional and expanded prescriber bases.

On a GAAP basis, net income for the quarter was $39.8 million, or $0.68 per diluted share, compared to $11.6 million, or $0.20 per diluted share, in Q2 2024. Non-GAAP adjusted net income, which we believe better reflects our core business performance, was $53.8 million ($0.92 per diluted share) for the second quarter of 2025 versus $24.5 million ($0.43 per diluted share) for the comparable 2024 period. This represents a 116% increase in adjusted profitability, highlighting our ability to grow both top-line revenue and bottom-line results while maintaining investments in our late-stage pipeline programs.

Reconciliations of applicable GAAP financial measures to Non-GAAP financial measures are included at the end of this press release.

Harmony’s operating expenses include the following:

• Research and Development expenses were $50.2 million in the second quarter of 2025, as compared to $63.6 million for the same quarter in 2024, representing a 21.1% decrease; primarily driven by a total of $42.6 million in IPR&D charges in Q2 2024 related to the Bioprojet sublicensing agreement for an orexin-2 agonist compound and acquisition of Epygenix, partially offset by a $15.0 million IPR&D charge related to the upfront fee from the 2025 CiRC Agreement that occurred this quarter;
• Sales and Marketing expenses were $30.1 million in the second quarter of 2025, as compared to $28.5 million for the same quarter in 2024, representing a 5.5% increase;
• General and Administrative expenses were $33.9 million in the second quarter of 2025, as compared to $27.2 million for the same quarter in 2024, representing a 24.6% increase; and
• Total Operating Expenses were $114.2 million in the second quarter of 2025, as compared to $119.3 million for the same quarter in 2024, representing a 4.3% decrease.

As of June 30, 2025, Harmony had cash, cash equivalents and investments of $672.3 million, compared to $576.1 million as of December 31, 2024.

2025 Net Product Revenue Guidance

Reaffirming full year 2025 net product revenue of $820 million to $860 million.

Conference Call Today at 8:30 a.m. ET

We are hosting our second quarter 2025 financial results conference call and webcast today, beginning at 8:30 a.m. Eastern time. The live and replay webcast of the call will be available on the investor relations page of our website https://ir.harmonybiosciences.com/.

To participate in the live call by phone, dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225.

Non-GAAP Financial Measures

In addition to our GAAP results, we present certain Non-GAAP measures including Non-GAAP adjusted net income and Non-GAAP adjusted net income per share, which we believe provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate Non-GAAP adjusted net income and Non-GAAP adjusted net income per share may not be identical to the manner in which other companies calculate adjusted net income and adjusted net income per share. We use these Non-GAAP measurements as an aid in monitoring our financial performance from quarter-to-quarter and year-to-year and benchmarking against comparable companies. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our Non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our Non-GAAP financial measures.

About WAKIX® (pitolisant) Tablets

WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients 6 years of age and older with narcolepsy. It was granted orphan drug designation for the treatment of narcolepsy in 2010, and breakthrough therapy designation for the treatment of cataplexy in 2018. WAKIX is a selective histamine 3 (H₃) receptor antagonist/inverse agonist. The mechanism of action of WAKIX is unclear; however, its efficacy could be mediated through its activity at H₃ receptors, thereby increasing the synthesis and release of histamine, a wake promoting neurotransmitter. WAKIX was designed and developed by Bioprojet (France). Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States.

Indications and Usage

WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.

Important Safety Information

Contraindications

WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment. WAKIX is contraindicated in patients with severe hepatic impairment and not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and at least twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory tract infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

In the placebo-controlled phase of the clinical trial conducted in pediatric patients 6 years and older with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and greater than placebo) for WAKIX were headache (19%) and insomnia (7%). The overall adverse reaction profile of WAKIX in the pediatric clinical trial was similar to that seen in the adult clinical trial program.

Drug Interactions

Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.

Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required.

H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.

WAKIX is a borderline/weak inducer of CYP3A4. WAKIX may reduce the effectiveness of sensitive CYP3A4 substrates, including hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.

Use in Specific Populations

There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.

The safety and effectiveness of WAKIX have not been established for treatment of excessive daytime sleepiness in pediatric patients less than 6 years of age with narcolepsy.

The safety and effectiveness of WAKIX have not been established for treatment of cataplexy in pediatric patients with narcolepsy.

WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.

WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with eGFR